It's shiny, it's new, it's a band-aid.

You're listening to Motley Fool Money.

I'm Ricky Mulvey, sitting in for Chris Hill, Austin Charmer joins us now, Austin Good

to See You.

Good to see you, Ricky.

Just a quick note, we will cover the Fed announcement on tomorrow's show.

It is a little past 2pm Eastern time right now, so we're not going to get to that or the

regional banks nonsense.

But there's a lot of earnings and even an IPO to talk about, Oset tomorrow, a very rare

thing is happening, which is that a company is going public.

Johnson and Johnson is spinning off Kenview, the consumer health stable, which includes

brands like Band-Aid, Tylenol, and Nutra Gina.

Is there a business reason to do this or is this just because analysts don't like mixing

multiples and mixed fractions are hard?

Company like Johnson, Johnson, very diversified, conglomerate business tends to mask some of

its strength by having this consumer health business nestled up beside a pharmaceutical

business.

The pharmaceutical revenue streams have a higher margin.

So management feels that if we spin off the consumer facing stuff, then maybe shareholders

will value us more for what we can produce the profits we're capable of at the same time.

A good consumer facing company, when it's managed by a set of dedicated capital allocators,

veterans, sometimes you can improve the speed at which that business accelerates and the

...